Protease and protease-activated receptor-2 signaling in the pathogenesis of atopic dermatitis.
Proteases in the skin are essential to epidermal permeability barrier homeostasis. In addition to their direct proteolytic effects, certain proteases signal to cells by activating protease-activated receptors (PARs), the G-protein-coupled receptors. The expression of functional PAR-2 on human skin and its role in inflammation, pruritus, and skin barrier homeostasis have been demonstrated. Atopic dermatitis (AD) is a multifactorial inflammatory skin disease characterized by genetic barrier defects and allergic inflammation, which is sustained by gene-environmental interactions. Recent studies have revealed aberrant expression and activation of serine proteases and PAR-2 in the lesional skin of AD patients. The imbalance between proteases and protease inhibitors associated with genetic defects in the protease/protease inhibitor encoding genes, increase in skin surface pH, and exposure to proteolytically active allergens contribute to this aberrant protease/ PAR-2 signaling in AD. The increased protease activity in AD leads to abnormal desquamation, degradation of lipid-processing enzymes and antimicrobial peptides, and activation of primary cytokines, thereby leading to permeability barrier dysfunction, inflammation, and defects in the antimicrobial barrier. Moreover, up-regulated proteases stimulate PAR-2 in lesional skin of AD and lead to the production of cytokines and chemokines involved in inflammation and immune responses, itching sensation, and sustained epidermal barrier perturbation with easier allergen penetration. In addition, PAR-2 is an important sensor for exogenous danger molecules, such as exogenous proteases from various allergens, and plays an important role in AD pathogenesis. Together, these findings suggest that protease activity or PAR-2 may be a future target for therapeutic intervention for the treatment of AD.
Lee
Sang Eun
SE
Department of Dermatology, Yonsei University College of Medicine, Gangnam Severance Hospital, 712 Eonju-ro, Gangnam-gu, Seoul 135-720, Korea.
Jeong
Se Kyoo
SK
Lee
Seung Hun
SH
D000890:Anti-Infective Agents / Q000494:pharmacology; D003876:Dermatitis, Atopic / Q000201:enzymology*; D010450:Endopeptidases / Q000378:metabolism; D006706:Homeostasis; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007249:Inflammation; D008954:Models, Biological; D008957:Models, Genetic; D010447:Peptide Hydrolases / Q000378:metabolism*; D044464:Receptor, PAR-2 / Q000378:metabolism*; D057057:Serine Proteases / Q000378:metabolism; D015398:Signal Transduction; D012867:Skin / Q000201:enzymology / Q000473:pathology; D016896:Treatment Outcome
D000890:Anti-Infective Agents; D044464:Receptor, PAR-2; D010450:Endopeptidases; D010447:Peptide Hydrolases; D057057:Serine Proteases